Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab

INTRODUCTION: Alzheimer’s disease (AD) is the most prevalent form of age-related dementia in the world. The body of evidence suggesting that its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein is robust. The d...

Descripción completa

Detalles Bibliográficos
Autores principales: Melo, V. S. D., Rodrigues, C. A., Silva, I. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434114/
http://dx.doi.org/10.1192/j.eurpsy.2023.663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434114/
http://dx.doi.org/10.1192/j.eurpsy.2023.663

Ejemplares similares